In information garnered via a Freedom of Information Act (FOI) lawsuit filed by Judicial Watch, Pfizer’s own study shows lipid nanoparticles (LNPs) in the mRNA COVID-19 vaccines enter your organs, especially the liver, adrenals, spleen, and ovaries.
Judicial Watch, Inc. is a conservative, non-partisan educational foundation that promotes transparency, accountability, and integrity in government, politics, and the law.
Judicial Watch announced it received 466 pages of records from the US Department of Health and Human Services (HHS) pertaining to Pfizer's biodistribution studies and related data for the COVID-19 vaccines.
Pfizer/BioNTech’s mRNA-based COVID vaccine relies on LNPs as a delivery system to enter cells. Pfizer said in a Jan. 10, 2022 press release Acuitas Therapeutics' LNP technology is used in COMIRNATY, the Pfizer/BioNTech COVID-19 vaccine.
The education foundation also received 663 pages of records from HHS regarding biodistribution studies and related data for COVID-19 vaccines, which show Johnson & Johnson relied on studies showing vaccine DNA particles and injected virus particles were still present in test animals months after injection.
Prior to another biodistribution study’s disclosure — obtained with a FOI in Japan in 2021 — the public was told by regulators and vaccine manufacturers the spike protein in the COVID vaccines remained at the injection site and was not biologically active despite many regulators around the world already having a copy of the study that demonstrated this was not the case.
A study published on the PubMed academic resource site for medical professionals regarding the safety profile of nanoparticles (NPs) also said NPs can get into human organs.
"Once they reach the blood circulation, NPs can be distributed and can accumulate in different organs such as the liver, spleen, lungs, and kidneys. Some studies suggest that NPs may also accumulate in the brain if they are small enough (<10 nm) and/or the blood brain barrier is not intact," it states on page four.
According to Judicial Watch, the Pfizer report noted when the lipid nanoparticles (LNPs) “with a comparable composition,” to that used in the Pfizer COVID vaccine were injected into rats, “Total recovery ... of LNP outside the injection site was greatest in the liver and was much less in the spleen, adrenal glands, and ovaries.”
Text in quotes here denotes Pfizer's study findings.
“In summary” … “the LNP distributes to the liver.” In the detailed analysis, the report states, “Over 48 hours, the LNP distributed mainly to liver, adrenal glands, spleen and ovaries, with maximum concentrations observed at 8–48 hours post-dose. Total recovery ... of LNP, for combined male and female animals, outside of the injection site was greatest in the liver (up to 18%) …,” Judicial Watch said.
A September 2020 “confidential” appendix to the clinical trial studies submitted for the Pfizer/BioNTech COVID vaccine, titled “Justification for the absence of studies in CTD Module 4” notes under “Safety Pharmacology” that “No safety pharmacology studies were conducted as they are not considered necessary according to the WHO guideline.”
"Carcinogenicity testing is generally not considered necessary to support the development and licensure of vaccine products for infectious diseases," Pfizer said.
In the same Pfizer study, the authors note, “Although liver function tests will be carefully monitored during the clinical development of these vaccines, BioNTech’s prior clinical experience indicates that the distribution to the liver does not pose a safety concern.”
Also, the Pfizer study authors note, “Based on previous nonclinical and clinical experience with the three RNA platforms, a beneficial safety profile is anticipated, and may include transient local reactions — such as swelling/edema or redness — and body temperature increases.”
The Johnson & Johnson records include a 2007 study of the biodistribution of an intramuscular-administered adenovector-based viral vaccine using New Zealand white rabbits, which showed that the vaccine accumulated in “the spleen, iliac lymph node, and the muscle at the site of injection.”
A table in the report shows the vaccine virus continued to appear in the rabbits’ iliac lymph nodes 180 days after injection.
“These documents show why many Americans have concerns about whether the novel COVID vaccines that were developed at such an accelerated pace were tested properly and thoroughly,” said Judicial Watch President Tom Fitton.